00000nam 2200000za 4500 9.850877 CaOODSP 20221107154246 cr ||||||||||| 180129s2018 onca o f000 0 eng d 9780660247205 9780660247212 CaOODSP eng n-cn--- NR16-202/2018E-PDF NR16-202/2018 National Research Council Canada. Blood-brain barrier carriers (L-11085, 11750, 12133, 12596, 12599, 12600) [electronic resource]. [Ottawa] : National Research Council Canada, 2018. [2] p. : col. ill. Issued also in French under title: Transporteurs pour franchir la barrière hémato-encéphalique (L-11085, 11750, 12133, 12596, 12599, 12600). Caption title. "February 2018." "The blood-brain barrier (BBB) is the principal hurdle in developing drugs for central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s, brain cancer, epilepsy and others. Composed of tightly adjoined endothelial cells, the BBB actively repels foreign matter from the brain; virtually no biologic molecules are able to cross it to elicit a therapeutic response. To address the need for disease-modifying CNS biologics, the NRC has developed carriers for delivering therapeutics beyond brain barriers. They can be coupled to a wide range of client molecules in order to prevent, diagnose, and treat CNS diseases"--Highlights, p. [1]. Issued also in print format. Drug carriers (Pharmacy) Blood-brain barrier Transporteurs pour franchir la barrière hémato-encéphalique (L-11085, 11750, 12133, 12596, 12599, 12600) (CaOODSP)9.850879 Blood-brain barrier carriers L-11085, 11750, 12133, 12596, 12599, 12600 (CaOODSP)9.850878 PDF 147 KB https://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-202-2018-eng.pdf